Venus Remedies has received DCGI permission for manufacturing and marketing its research product 'MEBATIC' after conducting a triple arm phase III comparative clinical trial study against ofloxacin and metronidazole therapies. This product is a wise fixed dose combination of flouroquinolone and nitroimidazole, and intended to be used in infusion form as one of the best solution for treatment of GI and GE problems associated with waterborne bacterial/plasmodial pathogens in humans. The company is planning to file dossiers of this product in developing countries to reap maximum benefit.
The development of the Mebatic is effective in eradicating E coli, Shigella sonnei, N. gonorrohoeae, G vaginalis, Yersinia enterocolitica, and S aureus. The combination has resulted in 20 per cent to 25 per cent efficacy over the ofloxacin and metronidazole alone therapies.
The health hazards of parasitic infections are well established specially in India and neighbouring countries. Mixed parasitic infection of intestine is most important contributory factor to anaemia. Anaemia due to hookworm disease is most serious problem of chronic suffering and disability in our rural population. Giardiasis and ascariasis are important causes of chronic illness, poor absorption of food and impaired growth and development of the children in India. Intestinal amoebiasis leads to lasting disability due to psychic problem.
Gastroenteritis is one of the most prevalent infectious diseases with repeat episodes. Diarrhoea, crampy abdominal pain, nausea, and vomiting are the most common symptoms. A survey in rural population of a hill district in North India revealed the presence of parasitic infection in 66 per cent of the population. Mixed infection was present in 33 per cent.
Mebatic will bridge the gap of long desired infusion therapy with wider spectrum, better efficacy and safety. His new infusion will reduce the hospitalization time and cost to patient and will be of great benefit to the ailing humanity. Indian pharmaceutical market was US$11.50 billion in 2008-09 and out of this the gastrointestinal drugs segment contributes to 10.7 per cent of total market making the GI market size of approximately US$1.23 billion.